Relay Therapeutics reports 11.1-month median PFS for zovegalisib plus fulvestrant at 400 mg BID fed in Phase 1/2 ReDiscover trial

Reuters03-16
<a href="https://laohu8.com/S/RLAY">Relay Therapeutics</a> reports 11.1-month median PFS for zovegalisib plus fulvestrant at 400 mg BID fed in Phase 1/2 ReDiscover trial

Relay announced Phase 1/2 ReDiscover trial data for zovegalisib plus fulvestrant at the recommended Phase 3 dose of 400 mg twice daily with food in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The results were presented at the ESMO Targeted Anticancer Therapies Congress 2026. In 57 efficacy-evaluable patients, median progression-free survival was 11.1 months and confirmed objective response rate was 43% (15/35) among patients with measurable disease. Relay said the ongoing Phase 3 ReDiscover-2 trial, initiated in mid-2025, is comparing zovegalisib plus fulvestrant versus capivasertib plus fulvestrant in patients who progressed on prior CDK4/6 inhibitor therapy. The company also reported that zovegalisib plus fulvestrant received FDA Breakthrough Therapy designation for the ReDiscover-2 trial population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603160700PRIMZONEFULLFEED9672323) on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment